Kidney cancer affects over 80,000 Americans annually, with renal cell carcinoma as the dominant type. Benjamin R. Lee, MD, MBA, outlines current AUA guideline recommendations, including when to…
Dr. Allison Betof Warner from Stanford University joins Rahul Gosain, MD and Rohit Gosain, MD, on the Oncology Brothers podcast to discuss melanoma treatment. The conversation covers the…
Rebecca L. Olin, MD, MSCE, associate professor in the Department of Medicine at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses changes in…
The constantly evolving science and emerging study results focused on adjuvant therapies have drastically changed the treatment landscape for patients with melanoma. Along with targeted therapies, immunotherapies have…
The research team led by Alexander Eggermont, MD, PhD, of the Gustave Roussy Cancer Campus Grand Paris, found that among over 1,000 stage III patients with melanoma treated…
Working with the theory that it would be possible to detect immune reinvigoration related to disease-free survival in various stages of melanoma, lead investigator Alexander C. Huang, MD,…
After prior case studies showed promising results with PD-1 inhibition followed by chemotherapy, a group of doctors, led by Georgia Sofia Karachaliou, MD, MSc, of the Department of Medicine…
A new analysis published in European Urology suggests that the risk window of recurrence for surgically treated renal cell carcinoma (RCC) may be longer than previously thought. Hoping…
Published final results of the DeCOG-SLT trial add evidence that patients who have a positive sentinel lymph-node biopsy, and have immediate complete lymph node dissection, do not achieve…
There have been many changes in the treatment landscape of stage II and stage III melanoma over the past decade. This article takes a look at the benefits…
Determining which patients are most likely to benefit from BRAF-targeted therapies was the topic of a recent review by Anna C. Pavlick, DO, MBA, of New York University…
Determining which patients are most likely to benefit from BRAF-targeted therapies was the topic of a recent review in ASCO Educational Book by Anna C. Pavlick, DO, MBA,…
